lkolodjeski:
Welcome to the biopharma marketing & social media chat (#socpharm). Please start w/intros & why u are interested in this. #socpharm
lkolodjeski:
We’ll assume that all tweets within #socpharm are your own and not your employers (unless you specifically declare them). #socpharm
lkolodjeski:
We’ll assume that all tweets within #socpharm are your own and not your employers (unless you specifically declare them). #socpharm
lkolodjeski:
Not familiar w/ me? I’m the community manager 4 @sanofi_diabetes & publish r division blog Discuss Diabetes http://t.co/Mbo3N9uL #socpharm
EileenOBrien:
@lkolodjeski: Thanks for guest moderating #socpharm tonight.
andrewspong:
Social metrics for Pharma http://t.co/hyHVVBeQ | Digital Rx #hcsmeu #socpharm #hcmktg
lkolodjeski:
@EileenOBrien: My pleasure, thanks for having me. #socpharm
robinrae22:
#socpharm Hi Laura nice to see you – look forward to hearing the discussion tonight.
pharmaguy:
@lkolodjeski: Hi Laura! #socpharm
lkolodjeski:
@robinrae22: Thanks so much. I was able to get your question in. So how about we begin? #socpharm
lkolodjeski:
@pharmaguy: Hey John, thanks for joining! #socpharm
lkolodjeski:
Let’s begin w/ any hot topics that emerged from #smpharma. Did the event surface any new discussion or same old, same old? #socpharm
lshawk:
Just joined the #socpharm chat #socpharm
EyeInfo:
RT @andrewspong: Social metrics for Pharma http://t.co/hyHVVBeQ | Digital Rx #hcsmeu #socpharm #hcmktg
EileenOBrien:
@lkolodjeski: #smpharma was good because there were some practical case studies shared, for example from @lillypad team. #socpharm
lkolodjeski:
@lshawk Welcome! #socpharm
EileenOBrien:
don’t think anything new was raised but it’s clear people are implementing programs, monitoring results & trying to move forward #socpharm
robinrae22:
@lkolodjeski: Didn’t attend #smpharm but did BI talk about its game Syrum? #socpharm
lkolodjeski:
@EileenOBrien: Was that the focus then? Learning from folks currently participating? #socpharm
lkolodjeski:
@robinrae22: I did not attend either. That’s why I was hoping there might be more discussion on the take-aways. #socpharm
EileenOBrien:
@robinrae22: No, @dcthmpsn discussed BI internal sm plans/policies at #smpharma. Amusing & informative. #socpharm
lkolodjeski:
But I’m happy to move on to a different question… #socpharm
AnnBartlett:
RT @lkolodjeski: : We’ll assume that all tweets within #socpharm are your own and not your employers (unless you specifically declare…
AnnBartlett:
RT @lkolodjeski: : Welcome to the biopharma marketing & social media chat (#socpharm). Please start w/intros & why u are interested in…
EileenOBrien:
@lkolodjeski: Yup! #socpharm
lkolodjeski:
Welcome to the chat Ann. Nice to have you! #socpharm
lkolodjeski:
So let’s move on then… #socpharm
lkolodjeski:
.@robinrae22: asked that we chat on how pharma can use pt cmmties to build trust/loyalty: should they & how? Thoughts? #socpharm
CarolSchiller:
@lkolodjeski: Heard about the #socpharm from @MDMonseau and @shwen. Hope it’s Ok if I pop in!
lkolodjeski:
@CarolSchiller: Of course. A pleasure to have you! #socpharm
crshorizon:
@lkolodjeski: Hi All – Pharma can identify the unmet needs of the pt commties and provide relevant content/resources. #socpharm
robinrae22:
@lkolodjeski: Along those lines – how are things going for Sanofi’s awarenss programs that have pt communities? #socpharm
EileenOBrien:
I worked on http://t.co/uzcYRnVJ w/Biomarin. It made sense for them bec no natl pt org, no community existed, only therapy 4 PKU #socpharm
lkolodjeski:
@robinrae22: I think we have found that with transparency & authenticity, u can build relationships & trust #socpharm
lkolodjeski:
But you should be clear about your intent, identify the value you can add, and add it #socpharm
pharmaguy:
@lkolodjeski: Pharma cant join some patient communities, such as ACOR. Listen to podcast: http://t.co/HQogP5ly #socpharm
robinrae22:
@lkolodjeski: Do u think this is better applied to some therapeutic categories than others? #socpharm
crshorizon:
RT @lkolodjeski: : @robinrae22: I think we have found that with transparency & authenticity, u can build relationships & trust #socpharm
robinrae22:
@lkolodjeski: And is transparency and trust the only end result, or are there others? #socpharm
lkolodjeski:
@robinrae22: Perhaps. Isn’t it about mtg ur customers where they are? Some categories may offer a more active online comm vs others #socpharm
robinrae22:
@lkolodjeski: What’s ur biggest challenge in making sure the pt communities add value? #socpharm
lkolodjeski:
@robinrae22: Transparency is required to earn trust & yes, we are finding additional benefits to our engagement in diabetes #socpharm
EileenOBrien:
@robinrae22: Are we talking about pharma-owned patient communities or sponsoring one on @inspire or @patientlikeme? #socpharm
lkolodjeski:
@EileenOBrien: Good Q as I was coming at it from participating in existing comm’s vs hosting one #socpharm
robinrae22:
@EileenOBrien: The end result for both shouild be the same – the difference is in the restrictions and risk managment , right? #socpharm
lkolodjeski:
@crshorizon: Totally agree. And thanks for joining. #socpharm
EileenOBrien:
@lkolodjeski: So how do you “jump in” to an existing pt community? Do you ask if u r welcome? #socpharm
pharmaguy:
@eileenobrien J&J owns a diabetes patient site, but only puts ads on the site, doesn’t engage as far as I know. #socpharm
lkolodjeski:
@pharmaguy: And others actually appreciate a presence from Pharma, eg TuDiabetes. Again, if u r clear abt ur intent. #socpharm
lkolodjeski:
@EileenOBrien: In my experience, yes. #socpharm
EileenOBrien:
@robinrae22: Restrictions & risk mgmt for sponsored comm would be same. But long-term commitment & resources less #socpharm
EileenOBrien:
@pharmaguy: That’s my understanding as well. Monitor & support community not engage. #socpharm
lkolodjeski:
Shall we move on to next question? #socpharm
lkolodjeski:
What are your thoughts on how pharma can better leverage communities to drive product/service innovation #socpharm
robinrae22:
@EileenOBrien: Agree. See them as gr8 resources w ability 2 improve healthcare outcomes, so would love to see more from all angles #socpharm
EileenOBrien:
@lkolodjeski: One more question to you: u r authorized to talk/engage generally about diabetes not brands I presume? #socpharm
EileenOBrien:
At #smpharma did hear a gr8 preso from @communispace about Lifescan private pt community they run for product dev & research #socpharm
lkolodjeski:
@EileenOBrien: Both, based on established parameters. #socpharm
SocMedSean:
Sorry for being late! Glad to join #socpharm tonight!
lkolodjeski:
Welcome Sean, thanks for joining. #socpharm
SocMedSean:
@lkolodjeski: Glad to be here! Catching up on the feed #socpharm
lkolodjeski:
@EileenOBrien: Were they able to share (broadly) what they have learned from the experience? #socpharm
EileenOBrien:
@lkolodjeski: Yes, Lifescan felt the community added excellent ideas, perspectives & insights. Now doing HCP one. #socpharm
lkolodjeski:
@EileenOBrien: So this is certainly one way to leverage communities to drive product/service innovation. Others? #socpharm
robinrae22:
@EileenOBrien: @lkolodjeski: This is gr8 stuff. Will b folloing up w u abt it soon. Sorry, but got 2 run. Tnx so much for the chat! #socpharm
SocMedSean:
@lkolodjeski: RE: pt commts – ideas, wishes, wants are shared on forums every day. Listening sparks ideas, which drives innovation #socpharm
lkolodjeski:
Ok, may be time to move to next topic… #socpharm
lkolodjeski:
Via MM&M Will Social Media Replace Surveys? I say why limit discussion to surveys? What about other aspects of mkt research? #socpharm
lkolodjeski:
@SocMedSean: Excellent point. We can all learn a lot by listening to the existing conversation as well #socpharm
EileenOBrien:
Here’s link to MM&M article http://t.co/amOeTXGq #socpharm
lkolodjeski:
The mkt research topic is on point w/ Communispace communities as well. Absolutely a form of (qual) research… #socpharm
lshawk:
@lkolodjeski: don’t think it will replace, but underscores the value of working with mkt research team on SM analytics program #socpharm
lkolodjeski:
@EileenOBrien: Thanks! My link was broken… #socpharm
lkolodjeski:
@lshawk Have u found it challenging to get MR to buy into the value of SM insights? #socpharm
crshorizon:
@lkolodjeski: Also – potential value of res. data from sm depends on whom you want to reach – only folks who use sm? #socpharm
SocMedSean:
Social isn’t very empirical & sentiment is often misinterpreted. Key is human analysis of the data, regardless of how collected. #socpharm
SocMedSean:
@crshorizon: Great point! Those who are socially savvy are generally a different demographic than those that aren’t #socpharm
EileenOBrien:
Right, Lifescan said even w/surveys of 100 people they considered @communispace research qualitative. #socpharm
CarolSchiller:
@pharmaguy: @eileenobrien That’s because of LMR concerns, correct? #socpharm
lkolodjeski:
Ok, let’s spend the last few minutes on a look ahead… #socpharm
lkolodjeski:
What are your predictions for how industry evolves or better leverages social media/mobile in 2012? #socpharm
lshawk:
@lkolodjeski: yes. But when they have, it enriches the program. Mkt research can help focus SM findings #socpharm
Murfomurf:
@EileenOBrien: Guess it depends on structure of surveys- some are too woolly; require too much free text to be really quanty. #socpharm
lkolodjeski:
@lshawk Totally agree. They are often able to add additional context that, as you say, helps focus the SM findings #socpharm
EileenOBrien:
@carolschiller Not sure which tweet u r referencing re LMR concerns #socpharm
richmeyer:
AstraZeneca To Lay Off 24% Of U.S. Sales Force As Of Feb. 2012 #hcsm #socpharm #mHealth #epharma #hcmktg #fdasm
cadelarge:
Thanks for great discussion tonight! #socpharm
lkolodjeski:
@EileenOBrien: Did you get the sense from #smpharma that more co’s are preparing to engage in 2012? #socpharm
SocMedSean:
@lkolodjeski: 2 Predictions: Pharma begins to recognize social isn’t a fad, but a biz opp. 2) No more waiting for FDA guidance
#socpharm
EileenOBrien:
@murfomurf yes, they also worried about different segments being represented #socpharm
lkolodjeski:
@richmeyer You should have joined us tonight! Moderating the tweet chat right now… #socpharm
richmeyer:
Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes #hcsm #socpharm #mHealth #epharma #hcmktg #fdasm
EileenOBrien:
@lkolodjeski: Yes think companies are realizing sm is business imperative. #socpharm
EileenOBrien:
@lkolodjeski: Yes think companies are realizing sm is business imperative. #socpharm
crshorizon:
@lkolodjeski: Relevance of mobile to grow in US & more in developing countries where it’s primary internet access for many #socpharm
lkolodjeski:
@EileenOBrien: That’s great to hear! And thanks @SocMedSean: for sharing your predictions! #socpharm
EileenOBrien:
Our time is up! Thanks@lkolodjeski: for gr8 job. I’ll post transcript #socpharm
lkolodjeski:
Thanks all for joining this evening! Appreciate the dialogue. #socpharm
SocMedSean:
@lkolodjeski: @EileenOBrien: – Thanks for the great chat! Happy Wednesday, everyone! #socpharm


Transcript from last night's #Socpharm tweetchat moderated by @kolodjeski is up: http://t.co/C3SZ5wjH.